Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
An update from Corbus Pharmaceuticals ( (CRBP) ) is now available.
Corbus Pharmaceuticals, an oncology and obesity-focused company, reported a net loss of $13.8 million for Q3 2024, attributing increased costs to clinical trials and compensation expenses. The company is advancing its diverse drug pipeline, including CRB-701 for cancer and CRB-913 for obesity, with significant data expected in early 2025. With $159.4 million in cash reserves, Corbus is poised to fund operations through Q3 2027 and continues to innovate in targeting well-understood biological pathways.
See more data about CRBP stock on TipRanks’ Stock Analysis page.
